ABOUT US About Celltrion Notice Media Center BUSINESS Business Areas R&D Production Distribution PRODUCTS Products Pipeline ESG Environmental Social Governance ESG Archive IR Financial Information Stock Summary Public Disclosures IR Archive CAREERS Our Values How to Apply Jobs KOR ENG Choose Other Countries Europe Asia Pacific North America Latin America close Denmark Finland (FI) Finland (SV) France Germany Hungary Ireland Italy Netherlands Norway (NO) Norway (SV) Spain Sweden Switzerland Portugal Türkiye United Kingdom Korea (HQ) Korea (EN) Japan Australia New Zealand Vietnam Canada (EN) Canada (FR) USA Brazil Chile Colombia Mexico Peru
ALL Discovery Spotlight ESG People All Title Content delete search Spotlight Meet Celltrion’s Europe Division, Leading Europe’s Direct-Sales Markets with 70% Market Share 2026.05.19 Discovery Inflammatory Bowel Disease (IBD): A Growing Global Health Challenge and the Evolving Treatment Paradigm Driven by Biopharmaceutical Innovation 2026.05.19 Discovery Formulation: Beyond Conventional Methods, Toward New Therapeutic Strategies 2025.09.29 Spotlight Celltrion's Open Innovation: Beyond Boundaries, Toward Innovation 2025.09.29 ESG Shaping a Better Future: Celltrion Releases 2024/25 Sustainability Report 2025.09.29 People Beyond Antibody Therapeutics: Celltrion’s Blueprint for Innovative Drug Development 2025.09.29 Discovery Celltrion’s Strategy for ADC Therapeutics 2025.05.14 Discovery Leading the Next Frontier in Biopharmaceutical Innovation 2025.05.14 Discovery Celltrion's Antibody Drug Manufacturing: Optimized Facilities and Cutting-Edge Technology 2025.05.14 First 1 2 Last
![[IBD Guide] From Causes to Advanced Therapies Like Infliximab | Celltrion](https://cellhomeblob.blob.core.windows.net/files/board/stories/261908350515-aa767f8e-bb40-42bd-bd6b-72ab8ad1c30c.png)
